gmp
gmp

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Golden Biotechnology

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              TAIWAN Taiwan

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              AAPS 2020 PHARMSCI 360

              Participation Not Confirmed

              Update your events

              Anti-viral and Anti-Inflammatory Response: GoldenBiotech's Antroquinonol Receives FDA Approval on COVID-19 Phase 2 Trial in USA

              Contact the Supplier

              Lead Product(s): Antroquinonol

              Therapeutic Area: Infections and Infectious Diseases Product Name: Hocena

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 01, 2020

              Details:

              The Phase II trial will be a randomized, double-blinded, placebo-controlled study of Antroquinonol as a potential treatment option for mild-to-moderate pneumonia in COVID-19 patients.

              PharmaCompass__DigitalAd